Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Considering the favorable preliminary data of few european diagnostic studies on dog detection, we develop in 2021 a pilot study in response to the plan of CHU Bordeaux and Nouvelle Aquitaine French region for an expanded, reliable and alternative rapid dog olfactory detection of COVID during pandemic period.
Our hypothesis is that validated olfactory detection on sweat or face mask collection by dogs would increase the acceptability and propensity to be tested in different population groups, given the non-invasive nature of sweat and face mask; compared to the unpleasant aspect of nasal swabs for PCR or rapid antigenic tests.
To reach this objective, we recruited a dog team to be trained and assessed (all-volunteers masters and dogs) and we will recruit participants with positive and negative PCR test. The diagnostic performance of canine olfactory detection of COVID-19 on sweat and face collection will be compared to the nasal SARS-Cov-2 PCR test of the participants.
The design of the study is an open,interventional risk-free, multi-centre diagnostic validation pilot sudy The main objective is the experimental assessment of the intrinsic diagnostic performance (sensitivity, specificity) among the first dog team in Nouvelle Aquitaine French region for the canine olfactory detection of COVID-19 on sweat samples from persons tested by PCR SARS-CoV-2.
The secondary objectives are :
This study will be conducted in two phases:
- Phase 1: experimental assessment of the intrinsic diagnostic performance (sensitivity, specificity) among the first dogs team in Nouvelle Aquitaine French region for the canine olfactory detection of COVID-19 on sweat samples and face mask from persons tested by PCR SARS-CoV-2.
The experimental assessment of the phase 1 wil include two experimental subpopulation samples of people tested by PCR SARS-CoV-2: positive, symptomatic or non-symptomatic (Case subpopulation); and negative non-case-contact, symptomatic or non-symptomatic (Control subpopulation).
- Phase 2: Near-routine live assessment of intrinsic and discriminating diagnostic performance (positive and negative predictive values) of dogs for the olfactory detection of COVID-19 on sweat collection and/or used face mask of persons rountinely screened by PCR SARS-CoV-2. These persons will be recruited consecutively without discrimination of subpopulations.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| sweat samples and used face mask will be collected | Diagnostic Test | Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test |
| Measure | Description | Time Frame |
|---|---|---|
| Experimentally validate the intrinsic diagnostic performance of dogs for the olfactory detection of COVID-19 | Combined measurement of a Sensitivity > 80% and a specificity > 60% of each dog and of all the dogs eligible for the week of evaluation of the canine olfactory detection of COVID-19; compared to the SARS-Cov-2 PCR test (gold standard) | day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Experimentally validate the intrinsic performance | Combined measurement of Sensitivity > 80% and Specificity > 60% of each dog and of all dogs eligible for the week of evaluation; in different subgroups of participants according to the presence of symptomatology, the presence of comorbidities, gender, hormonal cycle in women, taking medication, smoking and anti-COVID-19 vaccination | day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
-Common non-inclusion criteria: Age less than 6 years old History of COVID-19 confirmed by PCR test or rapid test or Scanner between Day 8 and Day 35 of the onset of symptoms -or of the test if asymptomatic) History of taste and / or smell disorder (s) that occurred between the Day 8 and Day 35 before pre-inclusion.
Confirmed or suspected long-haul symptoms of COVID-19 Patient subject to a judicial protection measure Person opposing the study (child or parent if minor) OR not understanding French
-Criteria for non-inclusion of witnessesControl participant : Contact case of COVID-19 for less than 35 days without having made PCR test between Day 5 and Day 8 of the contact Vaccination date against COVID of 7 days or less Professionals in human health or nursing homes or medical transport Woman in the middle of the menstrual cycle without pill or implant type contraception (ovulation) History of taste and / or smell disorders that occurred less than 7 days ago Hospitalization for more than 724 hours at the time of the sweat collection
Not provided
Not provided
Not provided
people screened by SARS-CoV2 PCR
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Thierry PISTONE, Dr | University Hospital Bordeaux, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Bordeaux, France | Bordeaux | 33000 | France | |||
| Hospital Dax |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D000086582 | Anosmia |
| D004194 | Disease |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Collection of sweat samples and face mask
| Experimentally validate the intrinsic performance | Combined sensitivity and specificity measurements for all dogs according to canine characteristics (breed, age, experience) and canine detection procedures (start or end of line, test days, sequence effects). | day 1 |
| Canine olfactory detection on mask | High concordance kappa coefficient of detection performance between the respiratory mask and the sweat samples (axillary and/or neck). | day 1 |
| Evaluation of the intrinsic and discriminative diagnostic performance of dogs for the olfactory detection of COVID-19 on sweat samples and/or used respiratory masks | mesure combinée pour les chiens, d'une Sensibilité > 80%, d'une spécificité > 60% et des valeur prédictives positive et négative qui dépendront de la prévalence de la COVID-19 au sein de l'échantillon qui sera recruté consécutivement sans discrimination de sous-population | day 1 |
| Dax |
| 40107 |
| France |
| Hospital Libourne | Libourne | 33505 | France |
| University Hospital Limoges, France | Limoges | 87042 | France |
| Hospital Périgueux | Périgueux | 24019 | France |
| Universtity Hospital Poitiers | Poitiers | 86021 | France |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000857 | Olfaction Disorders |
| D012678 | Sensation Disorders |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010335 | Pathologic Processes |